World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
USA
2026

D-Index & Metrics

Best Scientists

D-Index
205
Citations
157507
World Ranking
241
National Ranking
160

Medicine

D-Index
207
Citations
161201
World Ranking
141
National Ranking
96

Gabriel N. Hortobagyi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gabriel N. Hortobagyi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,609 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gabriel N. Hortobagyi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gabriel N. Hortobagyi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 207 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in United States Leader Award
  • 2023 - Research.com Medicine in United States Leader Award
  • 2015 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Gabriel N. Hortobagyi is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on Medicine, with significant contributions in Biochemistry, Genetics and Molecular Biology. Within these fields, they have a strong emphasis on Oncology and Cancer Research, alongside subfields such as Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

Their main research topics include:

  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Breast Lesions and Carcinomas
  • PARP inhibition in cancer therapy

Gabriel N. Hortobagyi has authored numerous papers, with recent notable publications including:

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, 2023, Journal of Clinical Oncology
  • TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis, 2021, Journal of Clinical Investigation
  • Ribociclib plus Endocrine Therapy in Early Breast Cancer, 2024, New England Journal of Medicine
  • Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis, 2021, Annals of Oncology
  • Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival, 2020, JNCI Journal of the National Cancer Institute

The scientist frequently publishes in the following journals:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • JAMA Oncology

Regular collaborators include:

  • William E. Barlow
  • Lajos Pusztai
  • Priyanka Sharma
  • Debu Tripathy
  • Daniel F. Hayes

Gabriel N. Hortobagyi was awarded Fellow of the American Association for the Advancement of Science (AAAS) in 2015.

Best Publications

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

    Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan

  • Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

    Benjamin D. Smith;Grace L. Smith;Arti Hurria;Gabriel N. Hortobagyi

  • Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

    Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

    Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

    Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis

  • Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

    Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar

  • Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

    Rita Nahta;Dihua Yu;Mien Chie Hung;Gabriel N. Hortobagyi

  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

    Weiyi Toy;Yang Shen;Helen Won;Bradley Green

  • Overview of Resistance to Systemic Therapy in Patients with Breast Cancer

    Ana Maria Gonzalez-Angulo;Flavia Morales-Vasquez;Gabriel N. Hortobagyi

  • Treatment of breast cancer

    Gabriel N. Hortobagyi

  • Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

    Sao Jiralerspong;Shana L. Palla;Sharon Hermes Giordano;Funda Meric-Bernstam

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

    P. A. Greenberg;G. N. Hortobagyi;T. L. Smith;L. D. Ziegler

  • Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

    Bryan T. Hennessy;Ana Maria Gonzalez-Angulo;Katherine Stemke-Hale;Michael Z. Gilcrease

  • PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients.

    Keng-Hsueh Lan;Yoichi Nagata;Xiaoyan Zhou;Francisco J. Esteva

Frequent Co-Authors

Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Ana M. Gonzalez-Angulo
Ana M. Gonzalez-Angulo The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Francisco J. Esteva
Francisco J. Esteva New York University
Richard L. Theriault
Richard L. Theriault The University of Texas MD Anderson Cancer Center
Aysegul A. Sahin
Aysegul A. Sahin The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the path to becoming a licensed physician. There are diverse online health degree options that can lead to rewarding roles within the healthcare system. For example, a popular route is earning a cheapest online healthcare administration degree, which can prepare you for leadership roles managing hospitals or clinics, often at a lower cost and with greater flexibility.

Those seeking advanced positions may consider the masters in healthcare administration cost to find programs that are both reputable and affordable. If you’re interested in clinical leadership or research, exploring the best dnp programs online can be a smart next step for current nurses aiming for the top of their field.

For those drawn to pharmaceuticals, accredited online pharmacy school programs offer flexible pathways to becoming a Doctor of Pharmacy (PharmD). Considering these related degrees and pathways can expand your options and help you achieve your professional healthcare goals.

Best Scientists Citing Gabriel N. Hortobagyi

Trending Scientists

Recently Published Articles